ASTRAZENECA PLC-SPONS ADR (AZN) Fundamental Analysis & Valuation
NYSE:AZN • US0463531089
Current stock price
189.75 USD
-2.55 (-1.33%)
At close:
189.5 USD
-0.25 (-0.13%)
After Hours:
This AZN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AZN Profitability Analysis
1.1 Basic Checks
- In the past year AZN was profitable.
- In the past year AZN had a positive cash flow from operations.
- AZN had positive earnings in each of the past 5 years.
- AZN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- AZN has a better Return On Assets (8.96%) than 90.05% of its industry peers.
- AZN has a better Return On Equity (21.01%) than 91.62% of its industry peers.
- AZN has a better Return On Invested Capital (13.63%) than 92.67% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 13.11%.
- The last Return On Invested Capital (13.63%) for AZN is above the 3 year average (12.48%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROIC | 13.63% |
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
1.3 Margins
- Looking at the Profit Margin, with a value of 17.41%, AZN belongs to the top of the industry, outperforming 90.05% of the companies in the same industry.
- In the last couple of years the Profit Margin of AZN has grown nicely.
- Looking at the Operating Margin, with a value of 23.86%, AZN belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
- In the last couple of years the Operating Margin of AZN has grown nicely.
- The Gross Margin of AZN (81.31%) is better than 86.39% of its industry peers.
- AZN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% |
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
2. AZN Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
- The number of shares outstanding for AZN remains at a similar level compared to 1 year ago.
- The number of shares outstanding for AZN has been increased compared to 5 years ago.
- Compared to 1 year ago, AZN has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.80 indicates that AZN is not in any danger for bankruptcy at the moment.
- AZN has a Altman-Z score of 3.80. This is in the better half of the industry: AZN outperforms 68.59% of its industry peers.
- AZN has a debt to FCF ratio of 3.42. This is a good value and a sign of high solvency as AZN would need 3.42 years to pay back of all of its debts.
- AZN has a better Debt to FCF ratio (3.42) than 89.53% of its industry peers.
- AZN has a Debt/Equity ratio of 0.55. This is a neutral value indicating AZN is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.55, AZN is doing worse than 67.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Altman-Z | 3.8 |
ROIC/WACC1.55
WACC8.8%
2.3 Liquidity
- A Current Ratio of 0.94 indicates that AZN may have some problems paying its short term obligations.
- Looking at the Current ratio, with a value of 0.94, AZN is doing worse than 88.48% of the companies in the same industry.
- A Quick Ratio of 0.72 indicates that AZN may have some problems paying its short term obligations.
- AZN has a Quick ratio of 0.72. This is amonst the worse of the industry: AZN underperforms 86.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 |
3. AZN Growth Analysis
3.1 Past
- AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.57%, which is quite good.
- The Earnings Per Share has been growing by 17.91% on average over the past years. This is quite good.
- The Revenue has grown by 8.63% in the past year. This is quite good.
- Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.15% on average per year.
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
3.2 Future
- The Earnings Per Share is expected to grow by 11.35% on average over the next years. This is quite good.
- Based on estimates for the next years, AZN will show a small growth in Revenue. The Revenue will grow by 6.31% on average per year.
EPS Next Y14.55%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
EPS Next 5Y11.35%
Revenue Next Year7.34%
Revenue Next 2Y6.88%
Revenue Next 3Y6.56%
Revenue Next 5Y6.31%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. AZN Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 20.56 indicates a rather expensive valuation of AZN.
- Based on the Price/Earnings ratio, AZN is valued cheaper than 82.20% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.42, AZN is valued a bit cheaper.
- With a Price/Forward Earnings ratio of 17.94, AZN is valued on the expensive side.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of AZN indicates a somewhat cheap valuation: AZN is cheaper than 79.58% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 22.24, AZN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.56 | ||
| Fwd PE | 17.94 |
4.2 Price Multiples
- 81.15% of the companies in the same industry are more expensive than AZN, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of AZN indicates a rather cheap valuation: AZN is cheaper than 80.63% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.94 | ||
| EV/EBITDA | 16.27 |
4.3 Compensation for Growth
- AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- AZN has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.24% in the coming years.
PEG (NY)1.41
PEG (5Y)1.15
EPS Next 2Y13.63%
EPS Next 3Y12.24%
5. AZN Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 1.59%, AZN has a reasonable but not impressive dividend return.
- AZN's Dividend Yield is rather good when compared to the industry average which is at 0.68. AZN pays more dividend than 91.10% of the companies in the same industry.
- AZN's Dividend Yield is comparable with the S&P500 average which is at 1.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.59% |
5.2 History
- The dividend of AZN has a limited annual growth rate of 3.33%.
- AZN has paid a dividend for at least 10 years, which is a reliable track record.
- AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)3.33%
Div Incr Years2
Div Non Decr Years12
5.3 Sustainability
- 48.62% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
- The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.62%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
AZN Fundamentals: All Metrics, Ratios and Statistics
189.75
-2.55 (-1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10 2026-02-10/bmo
Earnings (Next)04-29 2026-04-29
Inst Owners52.17%
Inst Owner Change-99.02%
Ins Owners0.04%
Ins Owner Change0%
Market Cap294.27B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts81.67
Price Target222.94 (17.49%)
Short Float %0.11%
Short Ratio0.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.59% |
Yearly Dividend3.21
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years2
Div Non Decr Years12
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.02%
Min EPS beat(2)-1.5%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)1.89%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)1.32%
EPS beat(12)7
Avg EPS beat(12)2.08%
EPS beat(16)11
Avg EPS beat(16)3.17%
Revenue beat(2)0
Avg Revenue beat(2)-1.57%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)-0.26%
Revenue beat(4)0
Avg Revenue beat(4)-1.84%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)-0.24%
Revenue beat(8)3
Avg Revenue beat(8)0%
Revenue beat(12)4
Avg Revenue beat(12)-0.5%
Revenue beat(16)5
Avg Revenue beat(16)-0.51%
PT rev (1m)7.17%
PT rev (3m)127.97%
EPS NQ rev (1m)-1.37%
EPS NQ rev (3m)92.68%
EPS NY rev (1m)-0.83%
EPS NY rev (3m)101.98%
Revenue NQ rev (1m)0.89%
Revenue NQ rev (3m)1.13%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.56 | ||
| Fwd PE | 17.94 | ||
| P/S | 5.01 | ||
| P/FCF | 33.94 | ||
| P/OCF | 20.19 | ||
| P/B | 6.05 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.27 |
EPS(TTM)9.23
EY4.86%
EPS(NY)10.57
Fwd EY5.57%
FCF(TTM)5.59
FCFY2.95%
OCF(TTM)9.4
OCFY4.95%
SpS37.88
BVpS31.38
TBVpS-6.72
PEG (NY)1.41
PEG (5Y)1.15
Graham Number80.7285 (-57.46%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROCE | 16.8% | ||
| ROIC | 13.63% | ||
| ROICexc | 14.63% | ||
| ROICexgc | 59.47% | ||
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% | ||
| FCFM | 14.76% |
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 103% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | 10.65 | ||
| Cash Conversion | 73.79% | ||
| Profit Quality | 84.79% | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 3.8 |
F-Score7
WACC8.8%
ROIC/WACC1.55
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
EPS Next Y14.55%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
EPS Next 5Y11.35%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year7.34%
Revenue Next 2Y6.88%
Revenue Next 3Y6.56%
Revenue Next 5Y6.31%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year25.58%
EBIT Next 3Y14.44%
EBIT Next 5Y10.4%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%
ASTRAZENECA PLC-SPONS ADR / AZN Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status for AZN stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
What is the profitability of AZN stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
What is the valuation of ASTRAZENECA PLC-SPONS ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 20.56 and the Price/Book (PB) ratio is 6.05.
Is the dividend of ASTRAZENECA PLC-SPONS ADR sustainable?
The dividend rating of ASTRAZENECA PLC-SPONS ADR (AZN) is 7 / 10 and the dividend payout ratio is 48.62%.